Skip to main content
Signal8

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 8-K — Jun 26, 2026

$CEROForm 8-KItems 1.01, 2.03, 3.02, 9.01Filed Jun 26, 2026, 8:00 AM ET0001213900-26-072602Original filing

CERO Therapeutics Holdings, Inc. entered into an amended and restated convertible promissory note with SRX Health Solutions, Inc., increasing the total available financing to $1,413,600. The agreement amends a previous $750,000 note issued in May 2026 and includes an immediate funding of $663,600 on June 23, 2026. The note matures on May 28, 2027, bears a 10% annual interest rate, and includes a 25% original issue discount that increases the principal obligation.

Key figures

Debt Amount
$1,413,600
Interest Rate
10%
Maturity Date
May 28, 2027
Floor Price
$0.05
Ownership Cap
4.99%
New Funding Date
June 23, 2026
New Funding Amount
$663,600
Conversion Discount
80% of lowest VWAP
Prior Funding Amount
$750,000
Original Issue Discount
25%

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 8-K — Jun 26, 2026: AI Analysis | Signal8